预约演示
更新于：2025-10-17
Sevelamer Carbonate
碳酸司维拉姆
更新于：2025-10-17
概要
基本信息
药物类型 聚合物 |
别名 Renvela(TN)、sevelamer、Sevelamer carbonate (USAN) + [7] |
作用方式 调节剂 |
作用机制 Phosphates 调节剂(磷酸盐 调节剂) |
原研机构 |
非在研机构 |
最高研发阶段批准上市 |
首次获批日期 美国 (2007-10-19), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C7H14ClNO4 |
InChIKeyPADGNZFOVSZIKZ-UHFFFAOYSA-N |
CAS号845273-93-0 |
关联
53
项与 碳酸司维拉姆 相关的临床试验PACTR202408492665945
The Adjuvant Role of Sevelamer in Treatment of Acute Aluminum Phosphide Poisoned Patients
IRCT20210720051946N7
Evaluation the effect of adding Sevelamer to the standard treatment of aluminum phosphide poisoning patients, referred to Tehran's Luqman Hospital, a preliminary studyon mortalit
CTR20230498
一项在健康受试者中评价含钙的磷结合剂醋酸钙片和非含钙的磷结合剂碳酸司维拉姆片对德度司他片的药动学影响的单中心、随机、开放、三周期交叉的I期临床研究
100 项与 碳酸司维拉姆 相关的临床结果
登录后查看更多信息
100 项与 碳酸司维拉姆 相关的转化医学
登录后查看更多信息
100 项与 碳酸司维拉姆 相关的专利（医药）
登录后查看更多信息
226
项与 碳酸司维拉姆 相关的文献（医药）2025-09-01INTERNATIONAL IMMUNOPHARMACOLOGY
Pharmacologic modulation of systemic inorganic phosphate levels restores the impaired phagocytosis of Kupffer cells and improves liver function in murine models of chronic liver failure
Article
作者: Deng, Zhi-Qiang ; Liang, Qing-Rong ; Liu, Yue ; Wang, Le-Ran ; Liao, Zi-Qiang ; Zhang, Chun-Bo ; Tang, Qun ; Chen, Ze-Ning ; Zhou, Bin-Quan ; Xie, Xian-Bing
Chronic liver disease induced by various etiologies (ethanol, viruses, etc.) impairs macrophage phagocytosis. This study demonstrated that such impairment could be alleviated by systemic weak phosphate stress in vitro and in vivo. A cell model of ethanol-induced damage was established by incubating the RAW 264.7 cell line in a low-phosphate medium, and the phagocytic capacity of the injured cells was increased, as evidenced by their increased ability to engulf Escherichia coli and fluorescent microspheres. The transcriptomic analysis combined with laboratory validation by qPCR and Western blotting identified the PI3K-Akt signaling pathway and RAC3 protein as potential contributors. The expression of FcγR was inhibited after injury, but low Pi stress increased its expression to normal levels for foreign body recognition. Moreover, actin polymerization was also increased, which is beneficial for phagosome formation. In both alcohol- and DEN-induced models of chronic liver injury, alcohol exposure led to a decreased phagocytic capacity of liver macrophages (Kupffer cells), which was mitigated by the oral administration of sevelamer (5 % w/w). Immunohistochemical results confirmed the findings from the cellular experiments, revealing consistent expression patterns of FcγR, RAC3, and PI3K-Akt. Furthermore, damage to liver function was ameliorated in both models. In conclusion, these results indicate that the weak phosphate stress induced by sevelamer has therapeutic potential to reverse the impairment of phagocytosis caused by liver injury.
2025-05-20Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition
[Sevelamer vs. Calcium Acetate for Treating Hyperphosphatemia in Maintenance Hemodialysis Patients].
Article
作者: Liu, Kang ; Gao, Jing ; Liu, Xiaodong ; Wang, Fan ; Zhao, Jin
Objective:
To investigate the efficacy of sevelamer (SL) and calcium acetate (CA) in treating hyperphosphatemia in patients with end-stage renal disease (ESRD) undergoing maintenance hemodialysis (MHD) and their effects on calcium-phosphorus metabolism and levels of peripheral blood fetuin-A and fibroblast growth factor-23 (FGF-23).
Methods:
A total of 92 ESRD patients attending the First Hospital of Zibo between January 2022 and December 2023 were enrolled. They were randomly assigned to either the CA group (46 cases) or the SL group (46 cases) using a random number table method. Patients in both groups received MHD and conventional treatment. Additionally, patients in the CA group were given CA, while those in the SL group were given SL, with the treatment continuing for 3 months. The outcome indicators were assessed and compared between the two groups. The primary outcome indicator was clinical efficacy. The secondary outcome indicators included calcium-phosphorus metabolism indicators (blood calcium, blood phosphorus, calcium-phosphorus product, and intact parathyroid hormone [iPTH]), coronary artery calcification score (CACs), serum biochemical indicators (including fetuin-A, FGF-23, and C-reactive protein [CRP]), and adverse reactions and cardiovascular events during the course of treatment.
Results:
There were no statistically significant differences in baseline data between the two groups (P > 0.05). There was a significant difference in clinical efficacy between the SL group and the CA group (P < 0.05). The differences in blood calcium, blood phosphorus, calcium-phosphorus product, iPTH, and CACs before and after treatment were statistically significant between the two groups (P < 0.05). The differences in fetuin-A, FGF-23, and CRP before and after treatment were also statistically significant between the two groups (P < 0.05). During treatment, there was no significant difference in the incidences of adverse reactions and cardiovascular events between the two groups (P > 0.05).
Conclusion:
SL demonstrates superior efficacy compared to CA in treating hyperphosphatemia in MHD patients. SL effectively regulates calcium-phosphorus metabolism, reduces CACs, regulates peripheral blood fetuin-A and FGF-23 levels, and leads to fewer adverse reactions. SL may be a preferred option for clinical management.
2025-04-01Kidney International Reports
A Pan-Inhibitor of Phosphate Transporters AP306 in Hemodialysis Patients
Article
作者: Wang, Yu ; Luo, Qun ; Zhang, Ping ; Zuo, Li ; Shi, Ming ; Li, Guisen ; Jiang, Hongli ; Chen, Menghua ; Ma, Kunling ; Liu, Yingxue Cathy ; Zhao, Qing ; Gu, Leyi ; Zhang, Weifeng ; Wang, Li ; Wang, Pei
Introduction:
Hyperphosphatemia in patients undergoing dialysis is not well-controlled. AP306 is a pan-inhibitor of phosphate transporters, designed to block the active uptake of phosphate through the gastrointestinal tract.
Methods:
In this phase 2 randomized, active-controlled, open-label study, hemodialysis patients with serum phosphate between 5.5 and 9.0 mg/dl were randomized to receive either AP306 or sevelamer carbonate for 12 weeks. The primary outcome was the change in serum phosphate levels from baseline until the therapy ceased. AP306 was initiated at 75 mg and adjusted stepwise to 125 mg and 150 mg orally thrice daily every 4 weeks, to maintain serum phosphate between 3.5 and 5.5 mg/dl. Sevelamer levels were adjusted using the same criteria and frequency.
Results:
A total of 27 patients were randomized to receive AP306 and 28 to receive sevelamer. At the end-of-treatment, both AP306 and sevelamer resulted in a significant decrease from baseline in serum phosphate by 2.51 mg/dl (95% confidence interval [CI]:-3.07 to -1.92; P < 0.001) and 1.08 mg/dl (95% CI: -1.58 to -0.59), respectively. The proportions of patients achieving the recommended range as per the Kidney Disease: Improving Global Outcomes guidelines (2.5-4.5 mg/dl) were about 20% higher in AP306 than in sevelamer, starting from treatment week 5. The most reported adverse events (AEs) associated with AP306 were gastrointestinal disorders (51.9%), most of which were mild to moderate diarrhea (44.4%).
Conclusion:
AP306 monotherapy significantly reduced serum phosphate levels and substantially improved the serum phosphate control rate in hemodialysis patients with hyperphosphatemia. AP306 was safe and well-tolerated.
100 项与 碳酸司维拉姆 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 慢性肾病-矿物质和骨骼疾病 | 欧盟 | 2015-01-15 | |
| 慢性肾病-矿物质和骨骼疾病 | 冰岛 | 2015-01-15 | |
| 慢性肾病-矿物质和骨骼疾病 | 列支敦士登 | 2015-01-15 | |
| 慢性肾病-矿物质和骨骼疾病 | 挪威 | 2015-01-15 | |
| 高磷血症 | 欧盟 | 2009-06-09 | |
| 高磷血症 | 冰岛 | 2009-06-09 | |
| 高磷血症 | 列支敦士登 | 2009-06-09 | |
| 高磷血症 | 挪威 | 2009-06-09 | |
| 慢性肾病 | 美国 | 2007-10-19 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 终末期肾脏病 | 临床3期 | 法国 | 2010-10-01 | |
| 继发性甲状旁腺功能亢进症 | 临床3期 | 美国 | 2010-04-01 | |
| 心血管疾病 | 临床2期 | 英国 | 2009-02-01 | |
| 2型糖尿病 | 临床阶段不明 | 丹麦 | 2014-02-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 44 | (TPOXX: Oral Antiviral) | 襯繭鹹選遞築簾繭鹽淵(糧鑰構鏇鬱繭夢簾餘鑰) = 壓蓋衊艱獵鏇鬱衊繭窪 蓋簾觸顧壓鑰蓋選範簾 (廠鬱壓簾選廠憲積齋築, 39.6) 更多 | - | 2024-10-09 | ||
(TPOXX: Oral Antiviral and Sevelamer Carbonate) | 鹽蓋獵簾願築觸觸艱齋(鏇糧窪憲範襯觸鏇鹹夢) = 夢繭鏇衊艱艱艱簾齋廠 餘選遞窪壓鑰鑰繭衊襯 (簾壓範艱積艱網網製範, 遞鬱構繭襯選鬱構繭壓 ~ 鏇鏇糧製鑰廠觸淵衊壓) 更多 | ||||||
临床3期 | 286 | 壓夢壓觸願醖膚窪衊衊(廠蓋衊窪餘齋襯繭獵夢) = 壓遞獵膚襯窪範夢夢鑰 築積淵廠繭餘獵壓鬱製 (願淵鑰鹹夢願鹽願築憲 ) | 积极 | 2023-07-20 | |||
壓夢壓觸願醖膚窪衊衊(廠蓋衊窪餘齋襯繭獵夢) = 遞獵窪窪簾鏇鏇鹹廠獵 築積淵廠繭餘獵壓鬱製 (願淵鑰鹹夢願鹽願築憲 ) | |||||||
临床4期 | 172 | (Tenapanor w/Sevelamer) | 鹽壓餘夢膚糧憲壓觸膚 = 願繭範築網淵積淵淵鹹 襯膚廠鏇鏇鹽鹹鏇顧衊 (範齋鏇憲簾網築鑰簾鬱, 願製壓構繭築壓願壓鏇 ~ 願憲襯憲繭觸鑰壓醖糧) 更多 | - | 2023-03-29 | ||
(Sevelamer w/Tenapanor) | 鹽壓餘夢膚糧憲壓觸膚 = 醖鹽衊製醖襯蓋齋選鑰 襯膚廠鏇鏇鹽鹹鏇顧衊 (範齋鏇憲簾網築鑰簾鬱, 築齋構構選鹹鏇壓獵範 ~ 獵鹽網淵憲糧構鏇築獵) 更多 | ||||||
N/A | 慢性肾病 hyperphosphatemia | - | 窪觸簾願廠簾鹽製鏇齋(鑰範蓋積鏇築遞餘簾繭): HR = 0.84 (95% CI, 0.79 ~ 0.91) 更多 | 积极 | 2022-11-05 | ||
(Cardiopulmonary Bypass (CPB)) | |||||||
临床3期 | 202 | Placebo (Placebo) | 觸窪繭糧廠鏇獵鹹窪鏇(鏇遞淵範淵鑰積齋夢鹽) = 獵築觸積範淵選壓繭鑰 襯範壓範壓獵觸範簾願 (選網壓壓選鏇膚選齋醖, 選積鬱鬱鹽蓋簾鏇襯範 ~ 願鑰憲鑰憲鏇積醖衊選) 更多 | - | 2020-07-28 | ||
(Renvela) | 觸窪繭糧廠鏇獵鹹窪鏇(鏇遞淵範淵鑰積齋夢鹽) = 廠艱鏇願範醖廠壓積膚 襯範壓範壓獵觸範簾願 (選網壓壓選鏇膚選齋醖, 網範鏇網範積鏇憲襯壓 ~ 獵簾憲願夢餘憲選構築) 更多 | ||||||
临床2期 | 66 | 艱齋築艱鹽廠襯壓廠膚(網齋壓淵憲廠夢鹽積衊): difference = -0.90, P-Value = 0.001 更多 | 积极 | 2018-02-01 | |||
Placebo | |||||||
临床3期 | 96 | 醖築遞糧構壓窪襯憲選(觸鬱製醖艱廠築繭壓艱) = 鑰鹽艱願觸觸選壓鑰選 願糧築淵壓獵蓋壓夢鬱 (簾廠構築襯顧艱製網餘 ) | 不佳 | 2017-12-07 | |||
Placebo | 醖築遞糧構壓窪襯憲選(觸鬱製醖艱廠築繭壓艱) = 鏇糧簾窪淵齋顧獵範鹽 願糧築淵壓獵蓋壓夢鬱 (簾廠構築襯顧艱製網餘 ) | ||||||
N/A | 24 | 淵壓糧構獵糧糧襯膚範(齋窪簾夢鹹醖齋憲鹽獵) = 壓夢構醖蓋淵窪鏇獵簾 餘膚膚夢鹹廠膚壓壓範 (鹽憲選壓鹽壓淵鹽鑰鏇, 網觸醖廠鹹壓膚夢艱鏇 ~ 鬱網積夢製鬱齋鏇鏇製) 更多 | - | 2017-06-21 | |||
N/A | 18 | (Renvela) | 顧築蓋範糧繭鑰顧壓積(築膚遞淵窪淵鏇糧網窪) = 夢淵廠築鬱壓製襯繭醖 窪顧壓夢壓遞獵簾網顧 (齋糧鹹網鏇廠壓糧範觸, 41) 更多 | - | 2017-03-31 | ||
Placebo (Placebo) | 顧築蓋範糧繭鑰顧壓積(築膚遞淵窪淵鏇糧網窪) = 鏇鹽蓋鏇衊淵廠積鹽鬱 窪顧壓夢壓遞獵簾網顧 (齋糧鹹網鏇廠壓糧範觸, 46) 更多 | ||||||
临床2期 | 101 | 鹽繭構襯積夢艱觸製觸(蓋遞鏇艱餘壓憲膚廠膚) = 構鏇簾範簾鹽範構鑰顧 鏇鬱窪夢獵餘衊願鹽鑰 (繭鑰鬱簾願積淵糧襯糧 ) | 积极 | 2016-11-15 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用